Aminoglycosides

On this page

Intro & MOA - Mighty Microbe Mincers

  • Potent bactericidal antibiotics.
  • Spectrum: Primarily aerobic Gram-negative bacilli.
  • Mechanism of Action (MOA):
    • Irreversibly bind to the bacterial 30S ribosomal subunit.
    • Interfere with protein synthesis:
      • Block initiation complex formation.
      • Cause mRNA misreading, leading to abnormal protein insertion.
      • Block translocation of peptidyl-tRNA.
    • Exhibit concentration-dependent killing (↑ conc. = ↑ killing rate).
    • Long Post-Antibiotic Effect (PAE).
    • Oxygen-dependent uptake (ineffective against anaerobes).
  • 📌 Examples: Gentamicin, Neomycin, Amikacin, Tobramycin, Streptomycin (GNATS).

⭐ Aminoglycosides cause misreading of mRNA and block translocation, leading to bactericidal action primarily against aerobic Gram-negative bacteria.

PK/PD Properties - Journey & Jolt

  • Pharmacokinetics (Journey - ADME):
    • Absorption: Poor oral (highly polar); IV/IM administration.
    • Distribution: Accumulates in renal cortex & inner ear (⚠️ nephro/ototoxicity risk).
    • Metabolism: Negligible.
    • Excretion: Renal, via glomerular filtration (unchanged). Adjust dose in renal failure.
  • Pharmacodynamics (Jolt - Effects):
    • Killing: Concentration-Dependent Killing (CDK) - higher $C_{max}$ = faster kill.
    • Duration: Significant Post-Antibiotic Effect (PAE) - suppression post-MIC drop.
  • Dosing Rationale:
    • Once-Daily Dosing (ODD) preferred:
      • Maximizes CDK with high peaks.
      • Utilizes PAE for sustained effect.
      • Minimizes toxicity (drug-free interval for washout from kidney/ear).

⭐ Once-daily dosing regimens leverage concentration-dependent killing and post-antibiotic effect to maximize efficacy and minimize nephrotoxicity.

Clinical Uses & Spectrum - Germ Warfare Gurus

  • Core Spectrum: Serious aerobic Gram-negative bacilli infections (Pseudomonas aeruginosa, E. coli, Klebsiella).

  • Synergy: With β-lactams/Vancomycin for Gram-positive endocarditis (Enterococcus, Staphylococcus).

  • Specific Pathogen Coverage:

    AminoglycosideKey Indications
    StreptomycinTuberculosis (TB), Plague, Tularemia
    GentamicinPlague, Tularemia, Serious Gram-negative sepsis
    AmikacinTB (MDR), Gentamicin-resistant Gram-negatives
    NeomycinBowel sterilization (oral), Topical infections
    TobramycinPseudomonas aeruginosa infections (esp. lungs)

⭐ Aminoglycosides are crucial in combination therapy with cell wall synthesis inhibitors (like penicillin or vancomycin) for synergistic bactericidal activity against certain Gram-positive cocci, especially in endocarditis.

Adverse Effects - Toxic Trio Alert

📌 NNN: Nephrotoxic, Neurotoxic (ototoxic), Neuromuscular blockade.

  • Nephrotoxicity:
    • Reversible acute tubular necrosis (ATN).
    • Monitor: Serum creatinine, BUN. Ensure hydration.
  • Ototoxicity:
    • Irreversible auditory (cochlear: hearing loss, tinnitus) & vestibular (vertigo, ataxia) damage.
    • Dose-related. Monitor audiometry in high-risk/long therapy.
  • Neuromuscular Blockade:
    • Rare; risk of respiratory paralysis.
    • Risk factors: Myasthenia gravis, rapid IV infusion, concurrent neuromuscular blockers, hypocalcemia.
    • Treatment: IV Calcium gluconate or neostigmine.

⭐ Ototoxicity from aminoglycosides can be irreversible and may manifest as hearing loss (cochlear damage) or vertigo/ataxia (vestibular damage).

Loading diagram…

Resistance & Interactions - Defense Breachers

  • Resistance Mechanisms:
    • Enzymatic modification (acetylation, phosphorylation, adenylation) - most common.
    • Impaired entry.
    • Altered ribosomal binding.
  • Key Interactions & Cautions:
    • Loop diuretics: ↑ ototoxicity.
    • Vancomycin/Amphotericin B: ↑ nephrotoxicity.
    • Neuromuscular blockers: ↑ blockade.
    • Pregnancy: Category D. ⚠️

⭐ Most common resistance: enzymatic drug inactivation by bacterial enzymes.

High‑Yield Points - ⚡ Biggest Takeaways

  • Bactericidal; irreversibly bind 30S ribosome, inhibiting protein synthesis.
  • Spectrum: Aerobic Gram-negative bacilli (e.g., Pseudomonas); synergistic with β-lactams.
  • Major toxicities: Nephrotoxicity (reversible ATN), Ototoxicity (irreversible; cochlear & vestibular), Neuromuscular blockade.
  • Administered IV/IM (poor oral absorption); exhibit significant post-antibiotic effect.
  • Resistance: Primarily via enzymatic modification (acetylation, phosphorylation).
  • Therapeutic Drug Monitoring (TDM) essential due to narrow therapeutic index.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Aminoglycosides

  1. 1. Which statement about lidocaine is NOT true?

    • A. Preferential resting-channel binding
    • B. Membrane penetration as unionized base
    • C. Receptor binding by cationic form
    • D. Binding within the intracellular pore
    Show answer

    Answer: A. Preferential resting-channel binding

    Preferential resting-channel binding is the incorrect statement: lidocaine binds more avidly to open or inactivated sodium channels. Membrane penetration as unionized base describes the lipid-soluble form that crosses the neuronal membrane. Receptor binding by cationic form describes the conventional intracellular blocking action of protonated lidocaine. Binding within the intracellular pore describes the receptor region, not an exclusive route of access; local anesthetics can access this region through hydrophilic and hydrophobic pathways.

  2. 2. Thioacetazone has cross-resistance with which of the following drugs?

    • A. Isoniazid (INH)
    • B. Rifampicin
    • C. Ethambutol
    • D. Ethionamide
    Show answer

    Answer: D. Ethionamide

    Ethionamide is the correct answer because mutations affecting shared EthA-mediated activation can confer cross-resistance with thioacetazone. Thioacetazone is a thiosemicarbazone whose activated form inhibits FAS-II dehydratases, whereas activated ethionamide inhibits InhA Isoniazid (INH) is activated mainly by KatG and inhibits InhA. KatG-mediated isoniazid resistance does not itself confer the EthA-linked cross-resistance tested here. Rifampicin - Rifampicin inhibits DNA-dependent RNA polymerase, rather than interfering with mycolic acid synthesis in the mycobacterial cell wall. - Its distinct target and mechanism mean rifampicin does not share the relevant activation pathway or cross-resistance mechanism with thioacetazone. Ethambutol - Ethambutol inhibits arabinosyl transferase and disrupts arabinogalactan synthesis, a different cell-wall pathway from thioacetazone. - Because it has a distinct target and metabolic pathway, resistance to ethambutol does not confer cross-resistance to thioacetazone.

  3. 3. Which of the following is NOT a mechanism of antibiotic resistance?

    • A. Drug efflux pump activity
    • B. Enzymatic drug inactivation
    • C. Drug target modification
    • D. Increased drug absorption
    Show answer

    Answer: D. Increased drug absorption

    Increased drug absorption - Increased drug absorption is not a bacterial resistance mechanism; it would generally increase antibiotic availability and intracellular concentration. - Resistance instead reduces the drug’s effective concentration or changes its target, whereas greater absorption would tend to enhance antibiotic activity. Drug efflux pump activity - Efflux pumps actively transport antibiotics out of bacterial cells, lowering the intracellular drug concentration. - Reduced drug levels prevent the antibiotic from reaching its therapeutic target, allowing bacterial survival and growth despite treatment. Drug target modification - Bacteria may alter antibiotic target sites, such as ribosomes or cell-wall components, through genetic mutations or other changes. - The modified target binds the antibiotic less effectively, reducing its ability to disrupt essential cellular processes. Enzymatic drug inactivation - Bacteria can produce beta-lactamase, an enzyme that chemically modifies or degrades susceptible antibiotic molecules. - This enzymatic inactivation is a common resistance mechanism against beta-lactam antibiotics, including penicillins and cephalosporins.

  4. 4. Anaerobes are resistant intrinsically against which of the following?

    • A. Aminoglycosides
    • B. Beta-lactam antibiotics
    • C. Nitroimidazoles
    • D. Macrolides
    Show answer

    Answer: A. Aminoglycosides

    Aminoglycosides require oxygen-dependent uptake, which is absent in obligate anaerobes. Nitroimidazoles are reductively activated in susceptible anaerobes rather than being universally ineffective against them. Beta-lactam antibiotics act against susceptible anaerobes, although beta-lactamase production can confer resistance. Macrolides have variable anaerobic activity rather than class-wide intrinsic resistance.

  5. 5. Rifampicin acts by inhibiting which of the following?

    • A. DNA gyrase
    • B. RNA-dependent DNA polymerase
    • C. DNA-dependent RNA polymerase
    • D. Enoyl-acyl carrier protein reductase
    Show answer

    Answer: C. DNA-dependent RNA polymerase

    DNA-dependent RNA polymerase - Rifampicin binds the β-subunit of bacterial DNA-dependent RNA polymerase, blocking initiation of RNA synthesis. - This inhibition of transcription is bactericidal and explains rifampicin's activity against Mycobacterium tuberculosis and other bacteria. RNA-dependent DNA polymerase - RNA-dependent DNA polymerase is also called reverse transcriptase, which synthesizes DNA from an RNA template in retroviruses. - Rifampicin instead targets bacterial transcription, so this enzyme is associated with antiretroviral therapy, not rifampicin's antibacterial mechanism. DNA gyrase - DNA gyrase is inhibited by fluoroquinolones, not rifampicin. - This enzyme is involved in DNA replication, whereas rifampicin directly inhibits bacterial RNA polymerase. Enoyl-acyl carrier protein reductase - Enoyl-acyl carrier protein reductase is targeted by isoniazid, which inhibits mycolic acid production in mycobacteria. - Rifampicin has a distinct target: the DNA-dependent RNA polymerase, so it does not directly inhibit mycolic acid synthesis.

  6. 6. For an adult with uncomplicated genital Chlamydia trachomatis infection, which antibiotic can be administered as a single oral dose?

    • A. Azithromycin
    • B. Erythromycin
    • C. Tetracycline
    • D. Doxycycline
    Show answer

    Answer: A. Azithromycin

    Azithromycin - Azithromycin inhibits bacterial protein synthesis by binding the 50S ribosomal subunit and is effective against uncomplicated genital chlamydial infection. - A 1-g oral dose provides prolonged exposure through azithromycin’s long half-life and tissue penetration, making it the single-dose regimen. Doxycycline - Doxycycline is effective against uncomplicated Chlamydia trachomatis infection but requires 100 mg twice daily for 7 days, so it is not a single-dose treatment. - Although doxycycline is often preferred for rectal chlamydial infection, its multidose regimen does not match the question’s single-dose requirement. Erythromycin - Erythromycin can treat chlamydial infection and may be used as an alternative in pregnancy, but it is not administered as a single dose. - Treatment generally requires a 7-day course, and gastrointestinal adverse effects commonly limit its tolerability. Tetracycline - Tetracycline is an older antichlamydial agent with a shorter half-life than doxycycline, requiring repeated daily dosing. - Its usual treatment involves a multiday regimen, so it does not provide the single-dose therapy requested in this question.

  7. 7. What is the primary clinical use of Sugammadex in anesthesia?

    • A. Treatment of central anticholinergic syndrome
    • B. Treatment of organophosphate poisoning
    • C. Reversal of neuromuscular blocking agents
    • D. Treatment of local anaesthetic poisoning
    Show answer

    Answer: C. Reversal of neuromuscular blocking agents

    Reversal of neuromuscular blocking agents - Sugammadex is a modified gamma-cyclodextrin that encapsulates steroidal neuromuscular blockers such as rocuronium and vecuronium. - This rapidly reduces active blocker concentration and produces dose-dependent reversal of neuromuscular blockade during anesthesia. Treatment of central anticholinergic syndrome - Central anticholinergic syndrome is typically treated with physostigmine, an acetylcholinesterase inhibitor that crosses the blood–brain barrier. - Sugammadex specifically binds steroidal neuromuscular blockers and has no role as a central anticholinergic antagonist. Treatment of organophosphate poisoning - Organophosphate poisoning is treated with atropine for muscarinic effects and pralidoxime to reactivate inhibited acetylcholinesterase. - Sugammadex does not antagonize organophosphates or regenerate acetylcholinesterase, so it is not used for this poisoning. Treatment of local anaesthetic poisoning - Local anesthetic systemic toxicity is managed with airway support, cardiovascular care, and lipid emulsion therapy when indicated. - Sugammadex does not bind local anesthetics and therefore has no efficacy in treating local anesthetic poisoning.

  8. 8. Which oral drug is commonly used to slow disease progression in subacute sclerosing panencephalitis?

    • A. Interferon
    • B. Inosiplex
    • C. Abacavir
    • D. Glatiramer
    Show answer

    Answer: B. Inosiplex

    Inosiplex - Inosiplex (inosine pranobex) is considered the oral drug of choice for SSPE, particularly early in the disease, and may delay progression. - It provides immunomodulation and enhances T-cell function, helping control persistent measles virus infection in the central nervous system. Interferon - Interferon-alpha may be administered intrathecally or intraventricularly as adjunctive treatment for SSPE. It is not an oral treatment and therefore does not answer the oral-treatment question. Abacavir - Abacavir is a nucleoside reverse transcriptase inhibitor used in combination antiretroviral therapy for HIV infection. - SSPE results from persistent measles virus infection, which is not treated by abacavir; therefore, it has no therapeutic role here. Glatiramer - Glatiramer acetate is an immunomodulator used primarily to reduce relapses in multiple sclerosis by altering immune responses to myelin. - It does not target persistent measles virus infection and therefore is not effective treatment for SSPE.

  9. 9. All of the following describe methicillin resistance in MRSA EXCEPT:

    • A. Reduced detection at 37°C
    • B. Mainly plasmid-mediated resistance
    • C. Increased beta-lactam MICs
    • D. Altered penicillin-binding proteins
    Show answer

    Answer: B. Mainly plasmid-mediated resistance

    Mainly plasmid-mediated resistance - This is the exception because resistance is primarily mediated by mecA, which is carried on the chromosomal SCCmec element rather than primarily on plasmids. - The mecA gene encodes PBP2a, while SCCmec integrates into the bacterial chromosome; therefore, plasmid transmission is not the principal mechanism. Reduced detection at 37°C - MRSA resistance expression can be heterogeneous and temperature-dependent, so testing at 37°C may occasionally fail to detect resistant subpopulations. - Incubation at 30–35°C and sometimes supplementation with 2–4% NaCl improves detection of methicillin resistance. Increased beta-lactam MICs - Acquisition of PBP2a reduces beta-lactam binding to the cell-wall synthesis machinery, producing decreased susceptibility. - Consequently, MRSA generally has increased MICs for methicillin and other beta-lactam antibiotics, consistent with its resistance phenotype. Altered penicillin-binding proteins - The mecA gene encodes an altered penicillin-binding protein, PBP2a, which has low affinity for beta-lactam antibiotics. - Because PBP2a continues supporting cell-wall synthesis despite beta-lactam exposure, altered PBPs produce methicillin resistance in MRSA.

  10. 10. In patients undergoing INH therapy, which group is least likely to develop neuropathy?

    • A. Patients with malnutrition
    • B. Patients with pyridoxine deficiency
    • C. Patients with alcohol dependence
    • D. Patients with rapid acetylation
    Show answer

    Answer: D. Patients with rapid acetylation

    Patients with rapid acetylation - Fast acetylators metabolize INH more rapidly, producing lower systemic drug exposure and reducing the likelihood of concentration-related adverse effects such as neuropathy. - Compared with patients having nutritional or pyridoxine deficiencies, rapid INH clearance is associated with the lowest neuropathy risk among the listed groups. Patients with malnutrition - Malnutrition commonly includes pyridoxine deficiency, reducing protection against isoniazid-associated neurotoxicity and increasing susceptibility to peripheral neuropathy. - This group is therefore more likely, not least likely, to develop neuropathy during INH therapy because poor nutritional status may deplete vitamin B6 reserves. Patients with pyridoxine deficiency - Vitamin B6 deficiency predisposes to INH-induced neuropathy because isoniazid interferes with pyridoxine metabolism and availability. - Patients with pre-existing B-complex deficiency have less nutritional protection against neurotoxicity, making neuropathy more likely rather than unlikely. Patients with alcohol dependence - Alcoholism is associated with poor dietary intake, impaired absorption, and vitamin deficiencies, particularly pyridoxine deficiency. - Because INH can further compromise pyridoxine metabolism, alcoholics are highly susceptible to neuropathy and are not the least-risk group.

Flashcards: Aminoglycosides

  1. 1. Which drug is used for the treatment of pregnant women with giardiasis?

    Show answer

    Paromomycin

  2. 2. Aminoglycosides exert _____-dependent killing and a _____ post-antibiotic effect

    Show answer

    concentration · long

  3. 3. Aminoglycosides are _____ compounds and are excreted usually unchanged in the _____

    Show answer

    polar · urine

  4. 4. The ototoxicity of aminoglycosides can cause either _____ or _____ damage

    Show answer

    vestibular · cochlear

  5. 5. Which aminoglycosides (3) have activity against _____?_____; _____; _____

    Show answer

    Pseudomonas · Gentamicin · Tobramycin · Amikacin

  6. 6. Which step ([A] - [E]) of Bacterial Protein Synthesis do Aminoglycosides inhibit? _____

    Show answer

    [B]

  7. 7. Which step ([A] - [E]) of Bacterial Protein Synthesis does Clindamycin inhibit? _____

    Show answer

    [D]

  8. 8. Which step ([A] - [E]) of Bacterial Protein Synthesis does Linezolid inhibit? _____

    Show answer

    [A]

  9. 9. Which group of modified penicillins is associated with the following rash? _____

    Show answer

    Amoxicillin, Ampicillin, Aminopenicillins

  10. 10. Which step ([A] - [F]) of Bacterial Genetics does Trimethoprim impact? _____

    Show answer

    [B]

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF